http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2021202839-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50eb752940fa4aa36756a6bc9f6f3504 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10 |
| filingDate | 2021-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71e8bc575a50e2e40d5fbcaac5f3317e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58e385a91928e512e991e5b342fe4ad0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b99c7e5a0c1dfef6cb8d0779701879f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c0c54114cc6e3b01b8e4e8c01865d9d |
| publicationDate | 2021-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2021202839-A1 |
| titleOfInvention | Human antibodies to ebola virus glycoprotein |
| abstract | The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, nthat bind to Ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies nand methods of use. The antibodies of the invention are useful for inhibiting or neutralizing nEbola virus activity, thus providing a means of treating or preventing Ebola virus infection in nhumans. In some embodiments, the invention provides for use of one or more antibodies that nbind to the Ebola virus for preventing viral attachment and/or entry into host cells. The nantibodies of the invention may be used prophylactically or therapeutically and may be used nalone or in combination with one or more other anti-viral agents or vaccines. n73n2/2 nFigure 2: Interaction of H1H17203, H1H17139P and H1H17161P with Ebola nGP.10xhis and Ebola soluble GP (sGP.mmh) at 25 °C n0.70 n0.00> nE0.50 n0.40 nC n0 .m 300 nM EBOV GP.1Oxhis Bind (nm) n0.30 =300 nM EBOV SGP.mmh Bind (nm) n300 nM hCNTFR.mmh Bind (nm) nS0.20 n0.10 n0.00 - --- ------- nHIH17203P H1H17139P HIH17161P n-0.10 nOctet HTX binding signals for each of the Ebola GP antibodies to 300nM Ebola GP.10xhis (black), nEbola soluble sGP.mmh (dark grey), and the irrelevant, negative control protein hCNTFR.mmh (light ngray). |
| priorityDate | 2015-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 713.